Drugs Containing Excipient (Inactive Ingredient) ARGININE

Branded drugs containing ARGININE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	AZACTAM	aztreonam	0003-2560	ARGININE
AbbVie Inc	EMBLAVEO	aztreonam and avibactam	0074-3878	ARGININE	2033-02-07
Allergan Inc	TEFLARO	ceftaroline fosamil	0456-0400	ARGININE
A-S Medication Solutions	AZACTAM	aztreonam	50090-7494	ARGININE
Physicians Total Care Inc	JENTADUETO	linagliptin	54868-6461	ARGININE
Actelion Pharmaceuticals US Inc	VELETRI	epoprostenol	66215-403	ARGININE

Generic drugs containing ARGININE excipient

Company	Ingredient	NDC	Excipient
ER Squibb & Sons LLC	aztreonam	0003-2560	ARGININE
Sanofi-Aventis US LLC	sarilumab	0024-5908	ARGININE
AbbVie Inc	aztreonam and avibactam	0074-3878	ARGININE
Novartis Pharmaceuticals Corporation	ofatumumab	0078-0669	ARGININE
Novartis Pharmaceuticals Corporation	ofatumumab	0078-1007	ARGININE
Hikma Pharmaceuticals USA Inc	cefepime hydrochloride	0143-9382	ARGININE

Last updated: August 23, 2026

Arginine is a low-cost, high-volume pharmaceutical excipient with limited standalone financial disclosure. Its commercial outlook is tied to biologics formulation, injectable products, amino-acid parenteral nutrition, oral solid-dose solubilization, and supplier qualification requirements. The market has attractive volume growth but modest pricing power because L-arginine and arginine hydrochloride are widely available commodities. Margin expansion depends on pharmaceutical-grade certification, low-endotoxin production, regulatory documentation, and reliable supply rather than molecule ownership.

Arginine Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is the pharmaceutical excipient market for arginine?

Arginine is used in pharmaceutical formulations primarily as a solubilizer, stabilizer, pH modifier, buffering component, tonicity agent, and amino-acid nutrient. It is supplied mainly as L-arginine or arginine hydrochloride.

The principal pharmaceutical applications are:

Application	Role of arginine	Commercial relevance
Biologic formulations	Reduces protein aggregation and improves solubility	Highest strategic value
Injectable products	pH adjustment, tonicity, solubilization	Requires stringent quality controls
Parenteral nutrition	Amino-acid source	High-volume, price-sensitive
Oral solid doses	Solubility enhancement and excipient functionality	Growing with poorly soluble APIs
Ophthalmic and specialty products	Stabilization and formulation support	Smaller, higher-compliance segment
Diagnostic and biotechnology media	Nutrient and buffering function	Adjacent demand

The market is fragmented among amino-acid manufacturers, specialty excipient suppliers, contract manufacturers, and distributors. Pharmaceutical-grade arginine competes with lower-cost material sold into food, sports nutrition, and industrial markets. The pharmaceutical premium is created by documentation, validated manufacturing, impurity control, traceability, and regulatory support.

How large is the arginine excipient market?

Public companies rarely report pharmaceutical-grade arginine revenue separately. Most suppliers combine arginine with broader amino-acid, nutraceutical, pharmaceutical ingredient, or specialty chemical sales. As a result, market estimates vary substantially depending on whether they include:

• Food-grade and nutraceutical L-arginine
• Pharmaceutical active pharmaceutical ingredient sales
• Pharmaceutical excipient use
• Parenteral nutrition products
• Contract manufacturing and distribution revenue

The pharmaceutical excipient segment is materially smaller than the total arginine market. Nutraceutical applications, including sports nutrition and cardiovascular supplements, account for significant global volume but do not establish pharmaceutical-grade pricing.

The main financial conclusion is that arginine is a scale and qualification market rather than a high-margin patented excipient market. Revenue growth is likely to track:

1. Expansion of injectable and biologic drug manufacturing.
2. Greater use of amino acids in protein formulation development.
3. Growth in parenteral nutrition and hospital products.
4. Increased demand for regional and dual-source supply.
5. Higher compliance costs for sterile and low-bioburden materials.

Industry reports commonly project mid-single-digit growth for broader amino-acid and pharmaceutical excipient categories, but those estimates should not be treated as audited revenue for pharmaceutical arginine alone.

What drives demand for pharmaceutical-grade arginine?

Biologics and protein formulation

Arginine is used in protein formulations because it can reduce protein-protein interactions, aggregation, and nonspecific adsorption in selected systems. Its effects depend on concentration, pH, ionic strength, protein structure, and the presence of other excipients.

This creates a commercially important distinction. A pharmaceutical customer may qualify a supplier based on a specific grade, impurity profile, particle-size distribution, endotoxin limit, and manufacturing site. Switching to another supplier can require compatibility testing, stability studies, and regulatory documentation.

Demand is therefore less elastic after qualification than commodity pricing alone would suggest.

Injectable and parenteral products

Arginine hydrochloride is relevant to injectable formulation work because it provides a defined salt form and can support pH and solubility control. Parenteral use imposes requirements for:

• Endotoxin control
• Bioburden limits
• Elemental impurities
• Residual solvents
• Microbial testing
• Sterility assurance where applicable
• Container-closure compatibility
• Lot-to-lot consistency

Suppliers with sterile-fill capability, validated depyrogenation controls, or established injectable-grade documentation can earn a premium over conventional amino-acid producers.

Parenteral nutrition

Arginine is included in amino-acid injection and nutrition products. This segment produces recurring volume but generally has lower margins than specialty biologic formulation because purchasing is concentrated among hospitals, nutrition-product manufacturers, and large pharmaceutical companies.

Pricing is affected by hospital procurement, generic competition, tender systems, and the availability of alternative amino acids. Demand is relatively stable but exposed to manufacturing disruptions and regional shortages.

Oral formulations

Arginine can improve the apparent solubility of certain active ingredients and may be used in oral liquids, powders, tablets, and granules. Oral applications expand the addressable market but usually generate weaker supplier lock-in than biologic or sterile applications.

What is the financial trajectory for pharmaceutical arginine?

The financial trajectory is best described as volume-led growth with moderate pricing pressure.

Financial variable	Expected direction	Explanation
Volume	Upward	Biologics, injectables, nutrition products, and emerging-market manufacturing
Base price	Stable to mildly pressured	Multiple global suppliers and amino-acid commoditization
Pharmaceutical-grade premium	Upward	Compliance, documentation, and supply assurance
Gross margin	Mixed	Higher for specialty and injectable grades; lower for bulk material
Working capital	Increasing in regulated channels	Safety stock and dual-site qualification requirements
Capital expenditure	Upward	Capacity, purification, environmental controls, and quality systems
Customer concentration	High	Large drug manufacturers purchase substantial volumes
Switching costs	Moderate to high	Higher for biologic and injectable formulations

Energy, feedstock, freight, and currency costs affect production economics. Arginine manufacturers also compete with suppliers that can divert capacity between pharmaceutical, food, feed, and nutritional markets. When non-pharmaceutical demand rises, pharmaceutical customers may face longer lead times even if total arginine supply remains adequate.

The most valuable commercial position is not necessarily the lowest-cost producer. It is a qualified supplier with multiple manufacturing sites, validated analytical methods, strong change-control procedures, and regulatory support in the United States, Europe, Japan, and China.

Which companies supply pharmaceutical-grade arginine?

The supply base includes major amino-acid manufacturers, pharmaceutical ingredient companies, and regional distributors. Relevant supplier groups include:

• Ajinomoto
• Kyowa Hakko Bio
• Evonik
• Merck and Sigma-Aldrich distribution channels
• Thermo Fisher Scientific and related laboratory supply channels
• Chinese and Indian amino-acid manufacturers
• Specialized excipient distributors serving Europe, North America, and Asia

Company-level pharmaceutical arginine revenue is generally not disclosed. Public filings typically report amino acids within larger nutrition, health-care, life-science, or specialty-ingredient segments.

Supplier competitiveness depends on:

• Manufacturing geography
• Fermentation and purification technology
• GMP compliance
• Pharmacopoeial conformity
• Regulatory support
• Availability of low-endotoxin or injectable grades
• Audit history
• Capacity redundancy
• Change-notification practices
• Distribution inventory

Ajinomoto and Kyowa Hakko Bio have strong positions in amino-acid manufacturing and regulatory-grade materials. Chinese and Indian producers exert price pressure, particularly in bulk and nonsterile applications. The competitive gap narrows when customers require validated pharmaceutical supply, but price competition remains intense for standard oral and nutrition grades.

What FDA regulatory status applies to arginine as an excipient?

FDA treatment depends on the formulation, route of administration, grade, and intended use. Arginine must be suitable for its specific use and supported by appropriate quality documentation.

The FDA Inactive Ingredient Database identifies excipients used in approved drug products and provides route- and dosage-form-specific precedent. Inclusion in the database is not a blanket approval for every formulation or concentration. Sponsors must still establish quality, safety, compatibility, and manufacturing controls for the intended product (U.S. Food and Drug Administration, n.d.-a).

Relevant regulatory sources include:

• United States Pharmacopeia-National Formulary standards
• European Pharmacopoeia monographs
• Japanese Pharmacopoeia standards where applicable
• FDA inactive-ingredient precedent
• ICH Q7 for active-substance GMP principles where relevant to manufacturing controls
• ICH Q8, Q9, and Q10 for pharmaceutical development, risk management, and quality systems
• Regional excipient and supplier qualification requirements

Food or nutraceutical acceptance does not establish suitability for parenteral drug products. Pharmaceutical users generally require a dedicated specification package, including identity, assay, related substances, elemental impurities, microbiological controls, residual solvents, and stability data.

What patents protect arginine as a pharmaceutical excipient?

The basic arginine molecule is long established and is not protected by a meaningful current composition-of-matter patent estate. Commercial protection arises mainly from formulation, process, use, and manufacturing patents.

Potentially relevant patent categories include:

Patent category	Typical subject matter	Exclusivity risk
Protein formulation patents	Arginine-containing biologic compositions	Medium to high in selected products
Solubility-enhancement patents	Arginine with a specific API or biologic	Product-specific
Manufacturing patents	Fermentation, purification, crystallization, or impurity removal	Variable
Combination patents	Arginine with surfactants, sugars, salts, or buffers	Narrow and claim-dependent
Delivery-system patents	Injectable, ophthalmic, nasal, or depot systems	Usually product-specific
Method-of-use patents	Use of arginine to stabilize or solubilize a named product	Limited to claimed use

No general “arginine excipient exclusivity” date exists. A formulation patent may expire years after the underlying arginine material became freely available.

When does arginine lose exclusivity?

Arginine itself has no commercially significant current exclusivity period comparable to a new drug substance. Generic and biosimilar entry risk instead depends on patents covering the finished product, formulation, delivery system, or manufacturing method.

For biologics, arginine may appear in a reference product formulation, but a biosimilar applicant does not automatically need to copy every excipient. The applicant must demonstrate biosimilarity and product quality under the applicable regulatory pathway. Formulation differences may be acceptable if they do not affect comparability, safety, purity, or potency.

What Orange Book status applies to arginine?

Arginine is not typically the subject of an Orange Book listing as an independently protected drug product. The Orange Book lists approved drug products and related patent and exclusivity information, not standalone excipient rights.

An arginine-containing product may have Orange Book patents if the finished product is an approved small-molecule drug. Those patents could cover:

• The active ingredient
• A specific formulation
• A dosage form
• A method of treatment
• A delivery technology

The listing attaches to the approved drug product, not to arginine as a general excipient. Paragraph IV litigation may therefore arise for a product containing arginine, but not because arginine itself has a general patent monopoly.

Which companies are challenging arginine-containing products?

There is no broad, identifiable Paragraph IV campaign directed at arginine as an excipient. Generic challenges target specific approved drug products. Relevant litigation must be reviewed at the product level through FDA Orange Book listings, Abbreviated New Drug Application certifications, district-court dockets, and patent settlements.

Biosimilar competition presents a more important strategic issue for arginine-containing biologic formulations. A biosimilar developer may:

• Use the same arginine concentration
• Use a different excipient system
• Retain arginine but change the buffer
• Develop a separate formulation for stability or manufacturability

The commercial effect is indirect. Increased biologic competition expands total demand for qualified excipients while reducing the exclusivity and pricing power of individual reference-product suppliers.

What manufacturing and intellectual-property barriers affect arginine?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Fermentation-based arginine production requires control of strain performance, feedstock quality, purification, crystallization, drying, and contamination. Pharmaceutical customers are sensitive to:

• Heavy metals and elemental impurities
• Biogenic impurities
• Residual host-cell materials
• Endotoxin
• Microbial contamination
• Polymorphism or solid-state variation
• Moisture and stability
• Traceability of raw materials

For injectable products, the cost of quality failure is high because a single out-of-specification lot can interrupt drug manufacturing.

Geographic coverage

Asia remains central to amino-acid production and intermediate supply. North America and Europe retain important roles in pharmaceutical-grade distribution, quality oversight, formulation development, and finished-dose manufacturing.

Customers increasingly seek regional redundancy because of:

• Pandemic-related logistics disruptions
• Export controls
• Port congestion
• Currency volatility
• Energy-price changes
• Geopolitical risk
• Single-site supplier exposure

A supplier with manufacturing in multiple regions can command stronger retention even when its nominal price is higher.

How strong is the patent estate for arginine?

The estate is weak for the excipient itself and potentially strong for selected finished-product formulations.

Asset type	Patent strength	Business implication
Free L-arginine	Low	Commodity exposure
Arginine hydrochloride	Low to moderate	Grade and process differentiation
Biologic formulation containing arginine	Moderate to high	Claim scope depends on concentration and combinations
Arginine-based solubilization method	Moderate	Vulnerable to design-around
Fermentation or purification process	Moderate	Can protect cost or quality advantages
Sterile injectable formulation	Moderate to high	Regulatory and technical switching costs

Patent review should focus on claim construction, concentration ranges, specified APIs, excipient combinations, and prosecution history. A claim requiring arginine in a narrow concentration range may be avoided by a formulation change. A claim covering a broad biologic formulation with defined stability performance can present greater entry risk.

What generic launch scenarios exist for arginine-containing drugs?

Three launch scenarios are most relevant:

1. A generic copies the finished product formulation and uses the same arginine grade or an equivalent grade.
2. A generic uses a different excipient composition and establishes bioequivalence or product comparability.
3. A biosimilar retains arginine but modifies the formulation to improve stability, injection volume, or manufacturing yield.

For standard oral products, launch risk is primarily patent and regulatory. For sterile injectables and biologics, supply qualification can delay commercial entry even after patent barriers fall.

Key Takeaways

• Pharmaceutical arginine is a mature, low-cost excipient with no meaningful standalone composition-of-matter exclusivity.
• Growth is linked to biologics, injectables, parenteral nutrition, and solubility-enhancement applications.
• Public filings do not isolate pharmaceutical arginine revenue, so financial analysis must use supplier segment data and end-market indicators.
• Standard material is price competitive; injectable, low-endotoxin, and fully documented grades have stronger margins.
• The strongest commercial barriers are qualification, quality systems, manufacturing redundancy, and regulatory support.
• Orange Book and Paragraph IV risk applies to specific arginine-containing drug products, not to arginine generally.
• Formulation and process patents can remain relevant even though the underlying excipient is long off-patent.
• Biosimilar competition may expand excipient volumes while reducing reference-product exclusivity.

FAQs

Is arginine an active pharmaceutical ingredient or an excipient?

It can be either. Arginine is an active ingredient in certain nutritional and therapeutic products and an inactive excipient in formulations where it improves solubility, stability, tonicity, or pH.

Is L-arginine interchangeable with arginine hydrochloride?

No. The salt form affects pH, ionic strength, solubility, osmolality, stability, and formulation performance. Substitution requires product-specific development and regulatory assessment.

Does pharmaceutical-grade arginine require a DMF?

A Drug Master File may support confidential manufacturing and quality information, but the requirement depends on the product, sponsor strategy, and regulatory jurisdiction. A supplier must still provide adequate information for qualification and regulatory review.

Can arginine improve biologic drug stability?

Yes, in selected formulations. Its effect is molecule-specific and may reduce aggregation or improve solubility, but it can also affect viscosity, charge interactions, and protein conformation.

Is arginine exposed to biosimilar price erosion?

Indirectly. Biosimilar entry can reduce prices for finished biologics, but it can increase aggregate demand for qualified excipients as more manufacturers produce competing biologic products.

References

European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

International Council for Harmonisation. (2000). Q7: Good manufacturing practice guide for active pharmaceutical ingredients. https://www.ich.org/page/quality-guidelines

International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. https://www.ich.org/page/quality-guidelines

International Council for Harmonisation. (2005). Q9: Quality risk management. https://www.ich.org/page/quality-guidelines

International Council for Harmonisation. (2008). Q10: Pharmaceutical quality system. https://www.ich.org/page/quality-guidelines

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

U.S. Food and Drug Administration. (n.d.-c). Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.